ESMO: Jazz HER2 bispecific posts 59% survival at 30 months in gastric cancer

cafead

Administrator
Staff member
  • cafead   Sep 16, 2024 at 10:12: AM
via Jazz Pharmaceuticals has posted fresh phase 2 data on zanidatamab that show the HER2-targeted bispecific antibody kept 59% of people with metastatic gastroesophageal cancer (mGEA) alive for at least 30 months when given in combination with chemotherapy.

article source